成人复发/难治性 B 细胞急性淋巴细胞白血病中贝林妥欧单抗与奥加伊妥珠单抗的真实世界患者结局：来自两家罗马尼亚肿瘤中心的回顾性分析

We conducted a retrospective analysis of 33 adult patients with R/R B-ALL treated between 2019 and 2023 at two major oncology centers in Romania.

Blinatumomab and Inotuzumab achieved complete remission rates of 47.6% and 90%, respectively, with measurable residual disease negativity in over 60% of responders. Inotuzumab was more effective in early relapses and cases with high disease burden, while Blinatumomab showed benefit in later relapses and post-transplant settings. Eleven patients were successfully bridged to allogeneic stem cell transplant, and four were treated for post-transplant relapse, demonstrating the feasibility of immunotherapy in both contexts. Sequential monoclonal antibody use yielded poor survival unless used as a bridge to curative therapy.

Our findings emphasize the need for individualized treatment selection, rational immunotherapy sequencing, and the development of predictive biomarkers to optimize outcomes and minimize toxicity. Further studies are needed to refine therapeutic algorithms and define such prognostic biomarkers, particularly in underfunded healthcare systems.